Current and new rotavirus vaccines

Purpose of review As of 2019, four rotavirus vaccines have been prequalified by the WHO for use worldwide. This review highlights current knowledge regarding rotavirus vaccines available, and provides a brief summary of the rotavirus vaccine pipeline. Recent findings Data generated from use of currently available products supports their effectiveness and impact in diverse settings. Rotavirus vaccines have a favorable risk–benefit profile, but previous associations of rotavirus vaccination with intussusception necessitate continued monitoring for this rare but serious adverse event. Implementation of rotavirus vaccines was jeopardized in late 2018 and 2019 by a shortage of vaccine supply. Fortunately, with the prequalification of two additional vaccines in 2018, countries have increased choice in products with different characteristics, pricing, and implementation strategies. Other vaccines currently in development may open up further immunization strategies, such as neonatal vaccination schedules or parenteral administration. Summary Rotavirus vaccines have demonstrated impact in reducing diarrheal morbidity and mortality worldwide. As countries begin to introduce the newly prequalified vaccines, additional data will become available on the safety and effectiveness of those products. Products in the pipeline have distinct profiles and could be an essential part of the expansion of rotavirus vaccine use worldwide.

[1]  Y. Poovorawan,et al.  Rotavirus infection in children in Southeast Asia 2008–2018: disease burden, genotype distribution, seasonality, and vaccination , 2020, Journal of Biomedical Science.

[2]  B. Bégaud,et al.  Quantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review , 2020, Open forum infectious diseases.

[3]  Hai Yu,et al.  Recent Progress on the Versatility of Virus-Like Particles , 2020, Vaccines.

[4]  A. Steele,et al.  Measuring Rotavirus Vaccine Impact in Sub-Saharan Africa , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  G. Kang,et al.  Rotavirus vaccine impact assessment surveillance in India: protocol and methods , 2019, BMJ Open.

[6]  J. Tate,et al.  Experiences with rotavirus vaccines: can we improve rotavirus vaccine impact in developing countries? , 2019, Human vaccines & immunotherapeutics.

[7]  R. Glass,et al.  Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species. , 2019, Vaccine.

[8]  U. Liebert,et al.  Rotavirus vaccine effectiveness in preventing hospitalizations due to gastroenteritis: a descriptive epidemiological study from Germany. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  J. Tate,et al.  Post-licensure experience with rotavirus vaccination in Latin America and the Caribbean: a systematic review and meta-analysis , 2018, Expert review of vaccines.

[10]  U. Parashar,et al.  Detection of rotavirus before and after monovalent rotavirus vaccine introduction and vaccine effectiveness among children in mainland Tanzania. , 2018, Vaccine.

[11]  E. Burnett,et al.  Preparing for safety monitoring after rotavirus vaccine introduction - Assessment of baseline epidemiology of intussusception among children <2 years of age in four Asian countries. , 2018, Vaccine.

[12]  J. Tate,et al.  Direct and possible indirect effects of vaccination on rotavirus hospitalisations among children in Malawi four years after programmatic introduction , 2018, Vaccine.

[13]  Jinyuan Wu,et al.  Isolation and characterization of a new candidate human inactivated rotavirus vaccine strain from hospitalized children in Yunnan, China: 2010-2013 , 2018, World Journal of Clinical Cases.

[14]  J. Tate,et al.  Effectiveness of monovalent rotavirus vaccine in the Philippines , 2018, Scientific Reports.

[15]  N. Gogtay,et al.  Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine☆ , 2018, Vaccine.

[16]  C. Murray,et al.  Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years , 2018, JAMA pediatrics.

[17]  A. Steele,et al.  Rotavirus Vaccines in China: Improvement Still Required. , 2018, JAMA network open.

[18]  Zhicong Yang,et al.  Rotavirus Gastroenteritis Infection Among Children Vaccinated and Unvaccinated With Rotavirus Vaccine in Southern China , 2018, JAMA network open.

[19]  Y. Nishida,et al.  Effectiveness of monovalent and pentavalent rotavirus vaccines in Japanese children. , 2018, Vaccine.

[20]  G. Kang,et al.  Safety monitoring of ROTAVAC vaccine and etiological investigation of intussusception in India: study protocol , 2018, BMC Public Health.

[21]  J. Tate,et al.  A decade of experience with rotavirus vaccination in the United States – vaccine uptake, effectiveness, and impact , 2018, Expert review of vaccines.

[22]  J. Tate,et al.  Impact of rotavirus vaccines in Sub-Saharan African countries. , 2018, Vaccine.

[23]  R. Grais,et al.  Safety of a heat-stable rotavirus vaccine among children in Niger: Data from a phase 3, randomized, double-blind, placebo-controlled trial. , 2018, Vaccine.

[24]  J. Tate,et al.  Evaluation of Intussusception after Monovalent Rotavirus Vaccination in Africa , 2018, The New England journal of medicine.

[25]  N. Xia,et al.  Expression and characterization of a novel truncated rotavirus VP4 for the development of a recombinant rotavirus vaccine. , 2018, Vaccine.

[26]  E. Burnett,et al.  Estimated impact of rotavirus vaccine on hospitalizations and deaths from rotavirus diarrhea among children <5 in Asia , 2018, Expert review of vaccines.

[27]  Katherine J. Lee,et al.  Human neonatal rotavirus vaccine (RV3-BB) targets rotavirus from birth , 2018, The New England journal of medicine.

[28]  Z. Duan,et al.  Faecal shedding of rotavirus vaccine in Chinese children after vaccination with Lanzhou lamb rotavirus vaccine , 2018, Scientific Reports.

[29]  M. Prausnitz,et al.  Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice , 2018, Scientific Reports.

[30]  U. Parashar,et al.  Decreased performance of live attenuated, oral rotavirus vaccines in low-income settings: causes and contributing factors , 2017, Expert review of vaccines.

[31]  J. Tate,et al.  Impact and effectiveness of pentavalent rotavirus vaccine in children <5 years of age in Burkina Faso. , 2017, Vaccine.

[32]  J. Tate,et al.  Impact of rotavirus vaccine on rotavirus diarrhoea in countries of East and Southern Africa. , 2017, Vaccine.

[33]  G. Kang,et al.  A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants , 2017, Vaccine.

[34]  E. Burnett,et al.  Global Impact of Rotavirus Vaccination on Childhood Hospitalizations and Mortality From Diarrhea , 2017, The Journal of infectious diseases.

[35]  Stephen S. Lim,et al.  Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Infectious diseases.

[36]  S. Gairola,et al.  Stability of heat stable, live attenuated Rotavirus vaccine (ROTASIIL®). , 2017, Vaccine.

[37]  S. Madhi,et al.  Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet. Infectious diseases.

[38]  S. Taneja,et al.  ROTAVAC® does not interfere with the immune response to childhood vaccines in Indian infants: A randomized placebo controlled trial , 2017, Heliyon.

[39]  A. Steele,et al.  The rotavirus vaccine development pipeline , 2017, Vaccine.

[40]  N. de Deus,et al.  Feasibility of using regional sentinel surveillance to monitor the rotavirus vaccine impact, effectiveness and intussusception incidence in the African Region. , 2017, Vaccine.

[41]  R. Grais,et al.  Efficacy of a Low‐Cost, Heat‐Stable Oral Rotavirus Vaccine in Niger , 2017, The New England journal of medicine.

[42]  N. Andrews,et al.  The risk of intussusception following monovalent rotavirus vaccination in England: A self-controlled case-series evaluation Ref. No: JVAC-D-16-01124. , 2016, Vaccine.

[43]  A. Vlasova,et al.  Skin Vaccination against Rotavirus Using Microneedles: Proof of Concept in Gnotobiotic Piglets , 2016, PloS one.

[44]  T. Vesikari,et al.  Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland , 2016, Journal of the Pediatric Infectious Diseases Society.

[45]  M. Estes,et al.  Rotavirus Serum IgA Immune Response in Children Receiving Rotarix Coadministered With bOPV or IPV , 2016, The Pediatric infectious disease journal.

[46]  U. Parashar,et al.  Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  J. Tate,et al.  Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  U. Parashar,et al.  Impact of Rotavirus Vaccine Introduction and Vaccine Effectiveness in the Republic of Moldova. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  U. Parashar,et al.  Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  T. Vesikari,et al.  Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine , 2015, Human vaccines & immunotherapeutics.

[51]  C. Yung,et al.  Intussusception and Monovalent Rotavirus Vaccination in Singapore: Self-Controlled Case Series and Risk-Benefit Study. , 2015, The Journal of pediatrics.

[52]  T. Vesikari,et al.  Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine , 2015, Archives of Virology.

[53]  Z. Duan,et al.  [Genotype of Rotavirus Vaccine Strain LLR in China is G10P[15]]. , 2015, Bing du xue bao = Chinese journal of virology.

[54]  Zhi‐Yong Zhang,et al.  Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case–control design , 2015, Emerging Microbes & Infections.

[55]  G. Kang,et al.  Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life. , 2014, Vaccine.

[56]  G. Kang,et al.  Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. , 2014, Vaccine.

[57]  G. Kang,et al.  Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial , 2014, The Lancet.

[58]  E. Belongia,et al.  Risk of intussusception after monovalent rotavirus vaccination. , 2014, The New England journal of medicine.

[59]  W Katherine Yih,et al.  Intussusception risk after rotavirus vaccination in U.S. infants. , 2014, The New England journal of medicine.

[60]  Katherine J. Lee,et al.  Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  T. Vesikari,et al.  Trivalent Combination Vaccine Induces Broad Heterologous Immune Responses to Norovirus and Rotavirus in Mice , 2013, PloS one.

[62]  R. Glass,et al.  Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? , 2013, Human vaccines & immunotherapeutics.

[63]  Ming Wang,et al.  Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. , 2012, Vaccine.

[64]  N. V. Trang,et al.  A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children , 2012 .

[65]  T. Vesikari,et al.  Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. , 2011, Vaccine.

[66]  Manish M Patel,et al.  Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. , 2011, The New England journal of medicine.

[67]  C. Fu.  Effectiveness of Lanzhou lamb rotavirus vaccine against hospitalized gastroenteritis: Further analysis and update , 2010, Human vaccines.

[68]  A. Steele,et al.  Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. , 2010, Vaccine.

[69]  R. Glass,et al.  Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. , 2010, Vaccine.

[70]  R. Glass,et al.  Development and characterization of candidate rotavirus vaccine strains derived from children with diarrhoea in Vietnam. , 2009, Vaccine.

[71]  Cecile Viboud,et al.  Trends in Intussusception Hospitalizations Among US Infants, 1993–2004: Implications for Monitoring the Safety of the New Rotavirus Vaccination Program , 2008, Pediatrics.

[72]  Ming Wang,et al.  Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study. , 2007, Vaccine.

[73]  T. Vesikari,et al.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. , 2006, The New England journal of medicine.

[74]  J. Heyse,et al.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. , 2006, The New England journal of medicine.

[75]  S. Huchette,et al.  Minerva Access is the Institutional Repository of The University of Melbourne , 2020 .

[76]  Santha Rama Rau.  to India , 2018 .

[77]  K. Soares-Weiser,et al.  Vaccines for preventing rotavirus diarrhoea: vaccines in use (Review) , 2012 .

[78]  J. Stockman.  Safety and Efficacy of an Attenuated Vaccine Against Severe Rotavirus Gastroenteritis , 2007 .

[79]  J. Stockman,et al.  Safety and Efficacy of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine , 2007 .

[80]  Withdrawal of rotavirus vaccine recommendation. , 1999, MMWR. Morbidity and mortality weekly report.

[81]  Robert J. Taylor,et al.  Rotavirus vaccines. , 1992, Biotechnology.